Intec Pharma Ltd. is merging with privately held Decoy Biosystems Inc. and the combined company will continue advancing Decoy’s immunotherapy technology for treating a variety of tumors and chronic viral infections.
Investors warmed to biopharma company equities, particularly in the final quarter of the year, with the BioWorld Biopharmaceutical Index increasing 23% in value during this period, helping the group climb to a respectable 14% for the year after being underwater from April through to September.